Eyenovia submits new drug application to fda for pharmacologic mydriasis with mydcombi targeting 80 million patient encounters in the u.s. annually

New york--(business wire)-- #fda--eyenovia has submitted an nda to the fda for mydcombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the optejet dispenser.
EYEN Ratings Summary
EYEN Quant Ranking